Cargando…

Inhibitors in haemophilia A and B: Management of bleeds, inhibitor eradication and strategies for difficult‐to‐treat patients

The standard therapy for patients with haemophilia is prophylactic treatment with replacement factor VIII (FVIII) or factor IX (FIX). Patients who develop inhibitors against FVIII/FIX face an increased risk of bleeding, and the likelihood of early development of progressive arthropathy, alongside hi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ljung, Rolf, Auerswald, Guenter, Benson, Gary, Dolan, Gerry, Duffy, Anne, Hermans, Cedric, Jiménez‐Yuste, Victor, Lambert, Thierry, Morfini, Massimo, Zupančić‐Šalek, Silva, Santagostino, Elena
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2018
Materias:	Review Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6936224/ https://www.ncbi.nlm.nih.gov/pubmed/30411401 http://dx.doi.org/10.1111/ejh.13193

Ejemplares similares

Switching treatments in haemophilia: is there a risk of inhibitor development?
por: Santagostino, Elena, et al.
Publicado: (2015)

Pain and pain management in haemophilia
por: Auerswald, Günter, et al.
Publicado: (2016)

Principles of care for acquired hemophilia
por: Dolan, Gerry, et al.
Publicado: (2021)

Autologous cell therapy – A new concept to eradicate inhibitors in haemophilia
por: Xie, Hanjing, et al.
Publicado: (2022)

Pharmacokinetics in routine haemophilia clinical practice: rationale and modalities—a practical review
por: Hermans, Cedric, et al.
Publicado: (2020)

The evolution of factor VIIa in the treatment of bleeding in haemophilia with inhibitors
por: Meeks, Shannon L., et al.
Publicado: (2019)

Comparison of Bypassing Agents in Bleeding Reduction in Treatment of Bleeding Episodes in Patients With Haemophilia and Inhibitors
por: Golestani, Mina, et al.
Publicado: (2014)

Treatment and Prevention of Bleeds in Haemophilia Patients with Inhibitors to Factor VIII/IX
por: Rocino, Angiola, et al.
Publicado: (2017)

European principles of inhibitor management in patients with haemophilia
por: Giangrande, P. L. F., et al.
Publicado: (2018)

The safety of activated eptacog beta in the management of bleeding episodes and perioperative haemostasis in adult and paediatric haemophilia patients with inhibitors
por: Escobar, Miguel, et al.
Publicado: (2021)

Successful Long Term Eradication of Factor VIII Inhibitor in Patients with Acquired Haemophilia A in Saudi Arabia
por: Zaher, Galila, et al.
Publicado: (2012)

International consensus recommendations on the management of people with haemophilia B
por: Hart, Daniel P., et al.
Publicado: (2022)

Eptacog beta efficacy and safety in the treatment and control of bleeding in paediatric subjects (<12 years) with haemophilia A or B with inhibitors
por: Pipe, Steven W., et al.
Publicado: (2022)

Concomitant use of bypassing agents with emicizumab for people with haemophilia A and inhibitors undergoing surgery
por: Jiménez‐Yuste, Victor, et al.
Publicado: (2021)

Haemophilia gene therapy: experiences and lessons from treated patients
por: Hermans, Cedric
Publicado: (2022)

Product type and the risk of inhibitor development in nonsevere haemophilia A patients: a case‒control study
por: van Velzen, Alice S., et al.
Publicado: (2020)

A phase 1b/2 clinical study of marstacimab, targeting human tissue factor pathway inhibitor, in haemophilia
por: Mahlangu, Johnny N., et al.
Publicado: (2022)

European principles of inhibitor management in patients with haemophilia: implications of new treatment options
por: Hermans, C., et al.
Publicado: (2020)

Real-World Utilisation and Bleed Rates in Patients with Haemophilia B Who Switched to Recombinant Factor IX Fusion Protein (rIX-FP): A Retrospective International Analysis
por: Hermans, Cedric, et al.
Publicado: (2020)

Achieving the unimaginable: Health equity in haemophilia
por: Skinner, Mark W., et al.
Publicado: (2019)

Efficacy of Corticosteroids Alone in the Eradication of Factor VIII Inhibitor in an Old Female with Idiopathic Acquired Haemophilia A: Description of a Case
por: Girelli, Francesco, et al.
Publicado: (2012)

Emicizumab in acquired haemophilia A: about two clinical cases and literature review
por: Hansenne, Amandine, et al.
Publicado: (2021)

Recombinant factor VIII Fc for the treatment of haemophilia A
por: Hermans, Cedric, et al.
Publicado: (2021)

Patient perspectives regarding gene therapy in haemophilia: Interviews from the PAVING study
por: van Overbeeke, Eline, et al.
Publicado: (2020)

How to translate and implement the current science of gene therapy into haemophilia care?
por: Hermans, Cedric, et al.
Publicado: (2023)

Bleeding pattern and consumption of factor VIII concentrate in adult patients with haemophilia A without inhibitors in the Czech Republic between 2013 and 2021 (Czech National Haemophilia Programme registry data)
por: Romanová, Gabriela, et al.
Publicado: (2023)

Vaccination against COVID‐19: Rationale, modalities and precautions for patients with haemophilia and other inherited bleeding disorders
por: Kaczmarek, Radoslaw, et al.
Publicado: (2021)

Consensus statements on vaccination in patients with haemophilia—Results from the Italian haemophilia and vaccinations (HEVA) project
por: Santagostino, Elena, et al.
Publicado: (2019)

The Role of Physiotherapy in the New Treatment Landscape for Haemophilia
por: Lobet, Sébastien, et al.
Publicado: (2021)

Epidemiological Challenges in Rare Bleeding Disorders: FVIII Inhibitor Incidence in Haemophilia A Patients—A Known Issue of Unknown Origin
por: Keipert, Christine, et al.
Publicado: (2020)

Frequency of Specific and Non-specific Inhibitors in Haemophilia A Patients
por: Ashfaq, Javeria, et al.
Publicado: (2022)

Management of haemophilia A with inhibitors: A regional cross‐talk
por: Peyvandi, Flora, et al.
Publicado: (2022)

Experience of Advate rAHF-PFM in previously untreated patients and minimally treated patients with haemophilia A
por: Auerswald, Guenter, et al.
Publicado: (2012)

Three-Dimensional Gait Analysis Can Shed New Light on Walking in Patients with Haemophilia
por: Lobet, Sébastien, et al.
Publicado: (2013)

Patient preferences for gene therapy in haemophilia: Results from the PAVING threshold technique survey
por: van Overbeeke, Eline, et al.
Publicado: (2021)

Challenges and key lessons from the design and implementation of an international haemophilia registry supported by a pharmaceutical company
por: Hay, Charles R. M., et al.
Publicado: (2020)

The Classification of Suspected Predominant Nociplastic Pain in People with Moderate and Severe Haemophilia: A Secondary Exploratory Study
por: Foubert, Anthe, et al.
Publicado: (2023)

Progress in the Development of Anti-tissue Factor Pathway Inhibitors for Haemophilia Management
por: Mahlangu, Johnny N.
Publicado: (2021)

ACTIVLIM‐Hemo: A new self‐reported, unidimensional and linear measure of activity limitations in persons with haemophilia
por: Lobet, Sébastien, et al.
Publicado: (2022)

The health and economic burden of haemophilia in Belgium: a rare, expensive and challenging disease
por: Henrard, Séverine, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_rse3395qiqi0pkrfs34fevnc4s